Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to DeAngelo, Daniel
Item TypeName
Academic Article KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Academic Article A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Academic Article PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease.
Academic Article Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
Academic Article Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Academic Article Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Academic Article Chronic myelogenous leukemia. Preface.
Academic Article Systemic mastocytosis: current classification and novel therapeutic options.
Academic Article Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
Academic Article Patient Management Issues with Imatinib Mesylate in CML and Other Hematologic Malignancies
Academic Article Fatal hepatic necrosis following imatinib mesylate therapy.
Academic Article Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Academic Article Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
Academic Article A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Academic Article How to treat chronic myeloid leukemia (CML) in older adults.
Search Criteria
  • Mesylates
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.